Background: This study evaluated the effects, safety, and tolerability of adjunctive brexpiprazole in adult patients with Major Depressive Disorder (MDD) who experienced an inadequate response to antidepressant monotherapy. Methods: This 12-week, multicenter, naturalistic, prospective observational study enrolled 60 adults with MDD and inadequate response to two or more antidepressant treatments who were prescribed adjunctive brexpiprazole. Outcomes in depressive symptoms, anxiety symptoms, illness severity, psychosocial functioning, and quality of life were assessed using the Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), Clinical Global Impressions–Severity (CGI-S), Clinical Global Impressions–Improvement (CGI-I), Sheehan Disability Scale (SDS), and World Health Organization Quality of Life–Brief Version (WHOQOL-BREF). Results: Fifty participants completed the week 12 assessment. Mean PHQ-9 scores decreased from 16.68 ± 5.64 at baseline to 11.50 ± 7.30 at week 12 (p < 0.001), and mean GAD-7 scores decreased from 13.32 ± 4.98 to 9.80 ± 5.63 (p < 0.001). At week 12, PHQ-9 response and remission rates were 38.0% and 22.0%, respectively; corresponding GAD-7 rates were 34.0% and 14.0%. Mean CGI-S scores decreased from 5.00 ± 1.16 to 3.52 ± 1.79 (p < 0.001); the mean week 12 CGI-I score was 2.44 ± 1.22. Mean overall SDS scores decreased from 16.00 ± 7.27 to 11.44 ± 8.36 (p < 0.001), with improvements across all domains. Conclusions: In clinical practice, adjunctive brexpiprazole was associated with early improvement in depressive and anxiety symptoms, illness severity, psychosocial functioning, and quality-of-life domains.
Background: This study evaluated the effects of adjunctive brexpiprazole in adult patients with Major Depressive Disorder (MDD) who experienced an inadequate response to antidepressant therapy. Methods: This 12-week, multicentre, naturalistic, prospective observational study enrolled 60 adults with MDD and an inadequate response to at least two antidepressant treatments. Depressive symptoms, anxiety, clinician-rated illness severity and improvement, functioning, and quality of life were assessed using the Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), Clinical Global Impressions—Severity (CGI-S) and —Improvement (CGI-I), Sheehan Disability Scale (SDS), and World Health Organization Quality of Life—Brief Version (WHOQOL-BREF). GAD-7 was assessed only at baseline and week 12. Inferential analyses used complete observations without imputation. Results: Fifty participants (83.3%) completed week 12 and contributed to the principal symptom analyses. Mean PHQ-9 scores decreased from 16.68 ± 5.64 to 11.50 ± 7.30, and GAD-7 scores from 13.32 ± 4.98 to 9.80 ± 5.63 (both p < 0.001). At week 12, PHQ-9 response and remission rates among these 50 participants were 38.0% and 22.0%; corresponding GAD-7 rates were 34.0% and 14.0%. Mean CGI-S decreased from 5.00 ± 1.16 to 3.52 ± 1.79 (p < 0.001); mean week-12 CGI-I was 2.44 ± 1.22. In 43 participants with all three SDS domains recorded at both visits, mean total SDS decreased from 16.79 ± 7.26 to 11.74 ± 8.65 (p < 0.001). Physical, psychological, and social relationship WHOQOL-BREF domains improved, whereas the overall quality-of-life item did not change significantly. Conclusions: In clinical practice, adjunctive brexpiprazole was associated with early improvement in depressive symptoms and improvements in anxiety symptoms, illness severity, psychosocial functioning, and quality-of-life domains.
About Me
Post-Graduate student in Psychiatry
Interest in the psychopharmacological research of depression and anxiety disorders
Post-Graduate student in Psychiatry
Interest in the psychopharmacological research of depression and anxiety disorders